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Background: The role of sirtuins in regulating platelet aging is largely unexplored.
Results: Sirtuin inhibitors induced apoptosis-like changes in blood platelets, associatedwith a rise in active Bax and a significant
drop in platelet count.
Conclusion: Sirtuins act as a central player in the determination of platelet aging.
Significance: This study refocuses attention on the potential side effect of sirtuin inhibition in delimiting platelet life span and
management of thrombosis.
Sirtuins are evolutionarily conserved NAD-dependent
acetyl-lysine deacetylases that belong to class III type histone
deacetylases. In humans, seven sirtuin isoforms (Sirt1 to Sirt7)
have been identified. Sirtinol, a cell-permeable lactone ring
derived from naphthol, is a dual Sirt1/Sirt2 inhibitor of low
potency, whereas EX-527 is a potent and selective Sirt1 inhibi-
tor. Here we demonstrate that Sirt1, Sirt2, and Sirt3 are
expressed in enucleate platelets. Both sirtinol and EX-527
induced apoptosis-like changes in platelets, as revealed by
enhanced annexin V binding, reactive oxygen species produc-
tion, and drop in mitochondrial transmembrane potential.
These changes were associated with increased phagocytic clear-
ance of the platelets by macrophages. Expression of acetylated
p53 and the conformationally active form of Bax were found to
be significantly higher in both sirtinol- and EX-527-treated
platelets, implicating the p53-Bax axis in apoptosis induced by
sirtuin inhibitors. Administration of either sirtinol or EX-527 in
mice led to a reduction in both platelet count and the number of
reticulated platelets. Our results, for the first time, implicate
sirtuins as a central player in the determination of platelet aging.
Because sirtuin inhibitors are being evaluated for their antitu-
mor activity, this study refocuses attention on the potential side
effect of sirtuin inhibition in delimiting platelet life span and
management of thrombosis.
Histone deacetylases (HDACs)3 are classified in four classes
depending on sequence identity and domain organization (1).
Sirtuins are evolutionarily conservedNAD-dependent acetyl-
lysine deacetylases that belong to the class III type of HDACs.
Sirtuins are involved in the regulation of metabolism and life
span (2). They are also implicated in determining the balance
between apoptosis, cell survival, and cell proliferation. In
humans, seven sirtuin isoforms (Sirt1 to Sirt7) have been iden-
tified, which localize either in the nucleus, cytoplasm, or mito-
chondria (3).
A number of studies have demonstrated that Sirt1 plays an
important role in the regulation of cell fate and stress response
in mammalian cells. Sirt1 promotes cell survival by inhibiting
apoptosis or cellular senescence induced by stresses such as
DNA damage and oxidative stress. Like Sirt1, Sirt2 is a ubiqui-
tous, nuclear, and cytoplasmic protein deacetylase (4). Sirt2 is
implicated in tumorigenesis and cell cycle regulation. An
increasing number of proteins have been identified as sub-
strates of Sirt1 and Sirt2, including p53, FoxO, and peroxisome
proliferator-activated receptor- (5). Sirtinol is a cell-permea-
ble six-membered lactone ring derived from naphthol and is a
dual Sirt1/Sirt2 inhibitor of low potency (6). Sirtinol has been
reported to induce senescence-like growth arrest in human
breast cancer cells as well as in H1299 and leukemic cells (7–9).
EX-527 is a potent and selective Sirt1 inhibitor (10).
Platelets, the enucleate blood cells derived frommegakaryo-
cytes, are discoid in shape, with size ranging between 2–4 m.
In response to vascular injury, platelets tether, adhere, aggre-
gate, and finally form platelet plugs in injured vessel walls to
arrest bleeding from blood vessels (11). HDAC inhibition has
been reported previously to affect platelet function (12, 13).
Inhibition of sirtuins with sirtinol attenuated the activation
phenotype of platelets, which included agonist-induced platelet
aggregation, a rise in intracellular Ca2, and the generation of
thromboxane B2 (6). However, it is not yet clear whether sir-
tuins have any role in platelet survival, as demonstrated for
other cells (7–9). Earlier studies, including ours, have shown
that delimitation of platelet life span involves balancing inter-
actions between Bcl-XL, Bax/Bak, and the proteasome system
(14, 15). Here we asked whether sirtuins have a regulatory role
in apoptosis-like events in platelets. In this study, we evaluated
the effect of three different pharmacological inhibitors of Sirt1/
Sirt2 on human and mouse platelets both under in vitro and in
vivo conditions. We demonstrated that Sirt1, Sirt2, and Sirt3
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are all expressed in enucleate platelets. We found that inhibi-
tors of sirtuin deacetylases, sirtinol, EX-527, and AGK2, mark-
edly stimulated apoptosis-like changes in platelets in a dose-de-
pendentmanner, as revealed by enhanced annexinV binding to
the platelet surface, generation of reactive oxygen species
(ROS), and disruption inmitochondrial transmembrane poten-
tial (m). Apoptosis-like changes in platelets were associated
with enhanced phagocytic clearance of cells by macrophages.
The apoptosis-like phenotype in platelets induced by sirtuin
inhibitorswas attributable top53-mediated transcription-inde-
pendent induction of proapoptotic Bax andwas calpain-depen-
dent. Administration of either sirtinol or EX-527 in mice
resulted in a decrease in both platelet count as well as in the
number of reticulated platelets.
EXPERIMENTAL PROCEDURES
ABT-737 was purchased from Selleck Chemicals. Annexin
V-FITC was from BD Biosciences. Rabbit polyclonal anti-p53,
acetyl-p53, Sirt1, and Sirt3 antibodies were procured from Cell
Signaling Technology. N-hydroxysuccinimidobiotin, phyco-
erythrin (PE)-streptavidin, JC-1, thiazole orange, carbonyl cya-
nide p-chlorophenylhydrazone, 6-carboxy-2,7-dichlorodihy-
drofluorescein, apyrase, EGTA, EDTA, sodium orthovanadate,
acetylsalicylic acid, bovine serum albumin (fraction V), rabbit
polyclonal anti-actin, Triton X-100, thrombin, protease inhib-
itors, DMSO, sirtinol, EX527, AGK2, tetramethylrhodamine
methyl ester (TMRM), acetyl-DEVD-7-amido-4-methyl cou-
marin, rabbit polyclonal Sirt2, andmousemonoclonal anti-Bax
(6A7) antibody were purchased from Sigma. Calcein-AM, TRI-
zol, and t-butoxy carbonyl-Leu-Met-chloromethyl coumarin
were from Invitrogen. RPMI 1640 medium and Hysep were
purchased from HiMedia. Diethylpyrocarbonate was bought
from Amresco. The high-capacity cDNA reverse transcription
kit was from Applied Biosystems. Sets of forward and reverse
primers were purchased from Eurofins and Operon. 2 SYBR
Green Supermixwas procured fromBio-Rad. Reagents for elec-
trophoresis were products of Merck. PVDF membranes and
Immobilon Western chemiluminescent HRP substrate were
from Millipore. HRP-labeled secondary antibody was pur-
chased from Bangalore Genei. All other reagents were of ana-
lytical grade. Milli-Q-grade type 1 deionized water (Millipore)
was used for preparation of solutions.
Platelet Preparation
Platelets were isolated from fresh human blood by differen-
tial centrifugation as described previously (16). The final cell
count was adjusted to 0.5–0.8  109/ml with a cell counter
(Beckman Coulter Multisizer 4). All steps were carried out
under sterile conditions, and precautions were taken to main-
tain the cells in a resting condition. Approval for the animal
experimentwas given by the university ethics review board, and
all human participants gave written informed consent. The
study was conducted according to the Declaration of Helsinki.
Cytofluorimetric Analysis of theMitochondrial
Transmembrane Potential
m was evaluated using the potential-sensitive fluoro-
chrome JC-1, which selectively moves across a polarized mito-
chondrial membrane and forms aggregates (red). As the mem-
brane potential collapses, the color changes from red to green
because of the release of monomeric dye (17). To study m,
platelets were pretreated with either sirtinol (50 or 100 M),
carbonyl cyanide p-chlorophenylhydrazone (100 M), or
DMSO (vehicle) for 30 min; AGK2 (100 M); or EX-527 (10 or
50 M); followed by incubation with 2 M JC-1 for 15 min at
37 °C in the dark. Cells were washed in PBS, and JC-1 fluores-
cence was analyzed in the FL1 and FL2 channels of a flow
cytometer (FACSCalibur, BD Biosciences) for detection of the
dye monomer and aggregates, respectively. Forward and side
scatter voltages were set at E00 and 273, respectively, with a
threshold of 52 V. An amorphous region (gate) was drawn to
encompass the platelets to differentiate from noise and multi-
platelet particles. The ratio of red to green (FL2/FL1) fluores-
cence reflected the mitochondrial transmembrane potential.
TMRM, another potential-specific dye that is sequestered by
active mitochondria, was also employed to study the effect of
sirtuin inhibitors. For evaluating the loss of mitochondrial
transmembrane potential, platelets were incubated with 1
g/ml TMRM for 15min prior to treatment with reagents (car-
bonyl cyanide p-chlorophenylhydrazone, 100 M; sirtinol, 100
M). TMRM-stained plateletswere analyzed in the FL2 channel
of the flow cytometer.
Flow Cytometric Measurement of ROS
Platelets pretreated with either sirtinol (50 and 100 M),
AGK2 (100M), EX-527 (10 or 50M), or vehicle (DMSO)were
washedwith PBS and incubatedwith 6-carboxy-2,7-dichloro-
dihydrofluorescein (1 M) for 30 min at 37 °C in dark. For a
positive control, platelets were treated with H2O2 (1%) for 10
min. Cells were again washed, and fluorescence was analyzed in
the FL1 channel of the flow cytometer. Sirtinol itself is fluores-
cent, and values for sirtinol were deducted from the observed
values in the experiments.
Measurement of Annexin V Binding by Flow Cytometry
Platelets (1 108 cells in 100 l) were incubated at 37 °C for
30 min in the presence of sirtinol (50 and 100 M), AGK2 (100
M), EX-527 (10 or 50 M), or vehicle (DMSO). For a positive
control, platelets were treated with thrombin (1 unit/ml) for 10
min without stirring and resuspended in annexin V-binding
buffer. Samples were incubated with 5 l of FITC-labeled
annexin V at room temperature for 30 min in the dark and
analyzed on the flow cytometer. Data from 10,000 CD61-posi-
tive events were collected for each sample.
Monocyte Isolation, Culture, and Phagocytic Recognition of
Platelets
Human monocytes were isolated and cultured as described
previously (18–19). Briefly, blood from healthy donors was col-
lected in citrate, and peripheral blood mononuclear cells were
isolated using Hysep according to the instructions of the man-
ufacturer. Monocytes were further isolated by plating the
peripheral blood mononuclear cells on polystyrene-coated
tissue culture flasks for 4 h at 37 °C, followed by three washes
with PBS to remove non-adherent lymphocytes. Monocytes
(250,000 in a 500-l volume) were then plated on 6-well plates
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in RPMI 1640 medium supplemented with 10% fetal bovine
serum and cultured for 7 days to obtain monocyte-derived
macrophages. Control and sirtinol (100 M)-treated platelets
labeled with calcein-AM were incubated with a monolayer of
autologous monocyte-derived adherent macrophages for 45
min. Following the incubation period, the phagocyte mono-
layer was washed to remove non-interacting platelets, and
adherent macrophages were removed by treatment with tryp-
sin at 37 °C for 5 min, followed by 5 mM EDTA at 4 °C. mono-
cyte-derived macrophages were recovered by trypsin/EDTA
treatment for 15 min at 37 °C and subjected to flow cytometric
and epifluorescense microscopic analysis.
Western Blotting
Proteins were separated by 10% SDS-PAGE and electropho-
retically transferred onto a PVDV membrane for 2 h at 0.8
mA/cm2 in a semidry blotter (TE 77 PWR, GE Healthcare). To
block residual protein binding sites, blotswere incubated for 1 h
with Tris-buffered saline containing 0.1% Tween 20 (TBST)
supplemented either with 5% (w/v) BSA (for Bax and Sirt2) or
with 5% skimmed milk (for acetyl-p53, p53, Sirt1, and Sirt3).
Membranes were incubated overnight with antibodies against
Bax (conformationally changed, clone 6A7, 1:500), acetyl-p53
(1:1000), p53 (1:1000), Sirt1 (1:1000), Sirt2 (2 g/ml), and Sirt3
(1:1000). To detect binding of the primary antibody, blots were
incubated with the appropriate horseradish peroxidase-conju-
gated secondary antibodies, diluted 1:10,000 in TBST for Bax
and 1:2500 in skimmed milk for acetyl-p53, p53, Sirt1, Sirt2,
and Sirt3, and exposed to enhanced chemiluminescence re-
agents for 5min. Blots were exposed to photographic films, and
the optical density was estimated using scanning densitometry.
For the protein loading control, membranes containing whole
cell lysates were reprobed with the anti--actin antibody.
Caspase-3 Activity Assay—To determine cytosolic caspase-3
activity, samples were pretreated with either sirtinol (50 and
100 M), EX-527 (10 and 50 M), or vehicle (DMSO) and lysed
with equal amounts of 2 radioimmune precipitation assay
buffer. After a 10-min incubation in ice, an equal volume of 2
substrate buffer (20 mM HEPES (pH 7.4), 2 mM EDTA, 0.1%
CHAPS, 5 mM DTT, and 10 M caspase substrate acetyl-
DEVD-7-amido-4-methyl coumarin) was added to each lysate
and further incubated for 30min at 37 °C (17). Caspase-3 activ-
ity was determined from the extent of cleavage of fluorogenic
substrate measured at 460 nm emission (excitation, 360 nm).
CalpainActivityAssay—Intracellularcalpainactivitywasmea-
sured as described previously (20). Washed human platelets in
96-well plates were exposed to either DMSO or sirtinol (50 and
100 M) or EX-527 (10 and 50 M) for 30 min and then loaded
with t-butoxycarbonyl-Leu-Met-chloromethylcoumarin (10
M). After 30 min of incubation, cellular fluorescence was
quantified with a fluorescence microplate reader (BioTek
FLx800) at 37 °C (excitation, 351 nm; emission, 430 nm).
Quantitative RT Real-time PCR
RNA Extraction—Platelets were isolated from human blood
as described above. Precaution was taken to prevent leukocyte
contamination. Cells were counted in a Beckman Coulter Mul-
tisizer 4. Total RNAwas extracted fromplatelets (2.5–2.8 108
cells/ml) using TRIzol reagent according to the protocol of the
manufacturer and suspended in diethylpyrocarbonate-treated
water.
Reverse Transcription—Platelet RNA (1 g) was transcribed
to cDNA using a high-capacity cDNA reverse-transcription kit
(Applied Biosystems) according to the instructions of the man-
ufacturer. Samples were amplified in a PTC-150 thermal cycler
(MJResearch) by using the following program: 25 °C for 10min,
37 °C for 120 min, and 85 °C for 5 min.
Quantitative Real-time PCR—Primers were designed using
the latest version of Primer3 Input software. The primers for
target gene (p53) were AGAGGAAGAG-AATCTCCGCA
(forward) and GTTTCTTCTT-TGGCTGGGGA (reverse).
GAPDH was used as the reference gene, and the primer
sequences for GAPDH were GAAGGTG-AAGGTCGGAGTC
(forward) and GAAGAT-GGTGATGGGATTTC (reverse).
We performed real-time PCR employing SYBR Green Super-
Mix in a CFX-96 real-time PCR system (Bio-Rad). Thermal
cycling conditions were as follows: 95 °C for 3 min, followed by
40 cycles consisting of 10 s of denaturation at 95 °C, 10 s of
annealing (at 56 °C in the case of GAPDH and 59 °C in the case
of p53 genes), and extension at 72 °C. A melt peak analysis of
amplicons was carried to rule out nonspecific amplifications.
Platelet Clearance Analysis
N-hydroxysuccinimidobiotin (600 mg) was injected into tail
vein of mice, followed by either DMSO (control) or sirtinol (15
mg/kg) (21). At various time points (0, 12, 36, 60, and 84 h), 25
l of retro-orbital blood was drawn from each mouse in the
control as well as treated groups, mixed with 200 l of buffered
saline glucose-citrate buffer (116 mM NaCl, 13.6 mM trisodium
citrate, 8.6 mMNa2HPO4, 1.6 mM KH2PO4, 0.9 mM EDTA, and
11.1 mM glucose (pH 7.3)), followed by 1 ml of balanced salt
solution (149 mM NaCl, 3.7 mM KCl, 2.5 mM CaCl2, 1.2 mM
MgSO4, 7.4 mMHEPES, 1.2 mMKH2PO4, 0.8 mMK2HPO4, and
3% bovine calf serum). Cells were pelleted at 1400  g for 10
min and resuspended in 300 l of sheath fluid. They were
stained with FITC-conjugated rat anti-CD41, which labels only
platelets, followed by PE-streptavidin for 1 h on ice. They were
then washed in balanced salt solution and analyzed by flow
cytometry to determine the fraction of the platelet population
labeled with PE (14).
Labeling of Reticulated Platelets
Mice were injected intravenously with either DMSO or sirti-
nol (15mg/kg), AGK2 (15mg/kg), or EX-527 (20mg/kg). Blood
was collected from the retro-orbital plexus of mice at different
time points (0, 12, 36, 60, and 84 h). Staining for reticulated
platelets was carried out by incubation of 5 l of blood with 50
l of thiazole orange (0.1 mg/ml in PBS) and 1 l of PE-conju-
gated CD41 antibody for 15 min at room temperature in the
dark, followed by fixation with 1 ml of paraformaldehyde (1%)
in PBS (14). Cells were washed with PBS, resuspended in 300l
of sheath fluid, and analyzed by flow cytometry. After appropri-
ate compensation, fluorescence data were collected using four-
quadrant logarithmic amplification. The number of thiazole
orange-positive platelets provided an estimate of new platelet
production. A platelet count was carried out using a cell coun-
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ter (Beckman Coulter Multisizer 4) at different time points (0,
12, 36, 60, and 84 h). After the experiment, the mice were sac-
rificed with an intraperitoneal injection of 2,2,2-tribromoetha-
nol (500 mg/kg).
Statistical Methods
Standard statistical methods were used. Parametric methods
(Student’s t test) were used for evaluation, and tests were con-
sidered significant at p  0.05 (two-tailed tests). All statistical
tests were carried out using Sigma Plot version 11 statistics
software. Data are presented as means  S.D. of at least three
individual experiments from different blood donors.
RESULTS
Human Platelets Express Sirt1, Sirt2, and Sirt3—Because
sirtinol is known to inhibit multiple sirtuin isoforms, we
checked for the presence of Sirt1, Sirt2, and Sirt3 in human
platelets by Western blot analysis. An earlier study has already
reported the expression of Sirt1 in human platelets (22). As
presented in Fig. 1, all three sirtuin isoforms were found to be
expressed in human platelets, which underscored the func-
tional relevance of these sirtuins in platelets.
Sirtuin Inhibition Induces Apoptosis-like Signaling inHuman
Platelets in Vitro—Sirtinol is known to possess antitumor activ-
ity and to induce apoptosis in several cancer cell lines (7–9). To
examine the effect of sirtuin inhibitors on platelets, we studied
m, an indicator of intrinsic cell death, in both sirtinol- as well
as EX-527-treated platelets. The lipophilic cation JC-1was used
to detect the drop in m by flow cytometry. Either of the
inhibitors evoked progressive dissipation of platelet m with
increasing concentrations (sirtinol, 50 and 100 M; EX-527, 10
and 50 M; Fig. 2A). Carbonyl cyanide p-chlorophenylhydra-
zone-treated platelets were employed as a positive control.
Similar results were observed when we substituted JC-1 with
TMRM, a pharmacologically distinctmitochondrialmembrane
potential probe (data not shown).
Phosphatidylserine redistribution from the inner to the outer
leaflet of the surface membrane is an early and widespread
event during apoptosis (23). Annexin V-FITC has a strong
Ca2-dependent affinity for phosphatidylserine and, therefore,
is used as a probe for the detection of apoptosis. Pretreatment of
platelets with increasing concentrations of either sirtinol (50
and 100 M) or EX-527 (10 and 50 M) resulted in a dramatic
increase in annexin V binding (by 42.0  5% and 80.7  5%,
respectively, for sirtinol and 23  5% and 120  5%, respec-
tively, for EX-527) compared with the untreated (control) cells,
indicative of induction of apoptosis-like events upon inhibition
of sirtuin (Fig. 2B). Thrombin-treated platelets were employed
as a positive control.
ROS play an important role in the initiation and execution of
apoptosis (24). We determined the effect of sirtuin inhibition
on the level of cytosolic ROS. The dye 6-carboxy-2,7-dichlo-
rodihydrofluoresceinwas used formeasurement of ROS, which
was oxidized to dichlorofluorescein by reactive oxygen species.
The results revealed a dose-dependent increase inROS in plate-
lets treated with either sirtinol or EX-527 (Fig. 2C). Hydrogen
peroxide-treated platelets were employed as a positive control.
Similar results were obtained when we substituted sirtinol with
AGK2, a pharmacologically distinct inhibitor of Sirt1/Sirt2
(data not shown).
Phagocytic Uptake of Sirtinol-pretreated Platelets by Macro-
phages—Platelets undergoing apoptotic changes are removed
by the reticuloendothelial system through the process of phag-
ocytosis, which eventually leads to the deletion of senescent
platelets (25).We evaluated themacrophage-assisted clearance
of platelets following Sirt1/Sirt2 inhibition. Calcein-stained
platelets pretreated with sirtinol (100M) or DMSOwere incu-
bated with a monolayer of autologous monocyte-derived
adherent macrophages for 45 min. The macrophage layer was
thenwashed to remove non-interacting platelets.Macrophages
were recovered by trypsin/EDTA treatment and subjected to
flow cytometry as well as fluorescence microscopic analysis to
examine the phagocytic uptake of platelets. For flow cytometry,
macrophages were gated, and calcein fluorescence (FL1) within
the “gate” was evaluated. Significantly higher fluorescence was
found to be associated with macrophages incubated with sirti-
nol-treated platelets than with those with untreated cells (Fig.
3A). This observation was further supported by fluorescence
microscopy, where significantly higher fluorescence was
recorded in macrophages incubated with sirtinol-pretreated
platelets in contrast to the control samples (Fig. 3B).
Apoptosis-like Changes Induced by Sirtuin Inhibitors Are
Mediated through Activation of the Proapoptotic Proteins Bax
and p53 and Are Calpain-dependent—Bax is a component of
the Bcl-2 gene family and is known to be expressed in platelets
(15). Although located in the cytoplasm, it undergoes confor-
mational change and mitochondrial translocation upon induc-
tion of apoptosis (26).We evaluated the effect of both sirtinol as
well as EX-527 on the expression of active Bax in human plate-
lets using an antibody specific for the conformationally active
form of the protein (clone 6A7). As expected, the BH3-mimetic
ABT-737 induced considerable activation of Bax in platelets.
Both sirtinol and EX-527 treatment led to significant incre-
ments in conformationally changed Bax in a dose-dependent
manner (Fig. 4A), suggestive of a critical role of Bax in sirtuin-
mediated changes in human platelets.
Acetyl-p53 is known to regulate the transcription-indepen-
dent pathway of apoptosis (27). The best characterized proapo-
ptotic function of p53 involves its translocation to mitochon-
FIGURE 1. Sirt1, Sirt2, and Sirt3 are expressed in humanplatelets. Platelet
proteins from twohealthy individualswere resolvedby SDS/PAGEand immu-
noblotted with antibodies directed against Sirt1, Sirt2, and Sirt3.
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FIGURE 2. Study of apoptosis-like features in platelets treated either with sirtinol or EX-527.Mitochondrial transmembrane potential (FL2/FL1 ratio, A),
phosphatidylserineexposure (FITC-annexinVbinding,B), andROSgeneration (C)were studied in control restingplatelets (RP) aswell as in cells pretreatedeither
with sirtinol or EX-527 as indicated. Data are mean S.D. of five different experiments. *, p 0.05 compared with DMSO-pretreated resting platelets. CCCP,
carbonyl cyanide p-chlorophenylhydrazone.
FIGURE 3. Phagocytic uptake of platelets by autologousmacrophages. Shown are flow cytometry (A) and epifluorescencemicroscopy (B) ofmacrophages
coincubatedwith calcein-labeled platelets pretreated either with sirtinol (100M) or DMSO (control). a and b represent phase-contrast micrographs, whereas
a’ and b’ represent corresponding fluorescent images. Data are representative of five different experiments.
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dria in stressed cells, where it interacts with Bcl-2 family
members and inducesmitochondrial outermembrane permea-
bilization through Bax activation. Acetylation prevents ubiq-
uitination of p53 and, therefore, promotes its stability by pro-
tecting it from proteasomal degradation (27). To understand
the molecular underpinnings of sirtinol- or EX-527-induced
changes, we studied the expression of acetyl-p53 in platelets
treated with the inhibitors. Progressive increments in acety-
lated p53were observedwhen cells were exposed to either sirti-
nol or EX-527 in increasing concentrations (Fig. 4B), therefore
implicating p53 and Bax in sirtuin inhibition-induced apopto-
sis-like signaling in platelets. Because the total p53 level was
unchanged in the presence of inhibitors, we checked for the
presence of p53 mRNA in platelets by real-time quantitative
PCR. The critical quantity values for p53 as well as GAPDH
(endogenous control) were found to be 30.7 and 23.35,
respectively (data not shown).These data strongly support a
significant presence of p53 mRNA in platelets that could
replenish protein loss because of proteasomal cleavage. A
melt peak analysis was performed to rule out nonspecific
amplification. Amplicons of GAPDH and p53 exhibited sin-
gle sharp peaks at 83.5 °C and 85 °C, respectively, suggestive
of a lack of nonspecific amplification. To the best of our
knowledge, this is the first report of expression of p53mRNA
in human platelets.
Bax and other proapoptotic proteins induce the release of
mitochondrial cytochrome c into the cytosol, which eventually
leads to caspase-3 activation (28). However, growing evidence
suggests that not all forms of programmed cell death are
caspase-mediated. Platelets, specifically, are known to undergo
caspase-independent cell death associated with the activation
of calpains (15, 20, 29–31). To determine whether caspase-3 is
involved in either sirtinol- or EX-527-mediated apoptosis-like
changes in platelets, we measured its activity from cleavage of
the fluorogenic substrate DEVD-AMC in platelets pretreated
with the inhibitor orDMSO (vehicle). No significant increase in
caspase-3 activity was detected in either sirtinol- or EX-527-
treated platelets compared with control cells (Fig. 4E), consis-
FIGURE 4. Sirtinol-induced apoptosis-like changes in platelets aremediated throughBax, p53, and calpain. A, Western blots representing expression of
active Bax (top panel) and -actin (loading control, bottom panel) in platelets pretreated with either DMSO (RP), sirtinol, EX-527, or ABT-737. B, Western blots
representing expression of acetyl-p53 (top panel) and p53 (loading control, bottompanel) in platelets pretreatedwith either DMSO, sirtinol, or EX-527. C andD,
corresponding densitometric analyses representative of at least five independent immunoblots each for active Bax and acetyl-p53 normalized against actin
or p53, respectively. E, caspase-3 activity determined from the extent of cleavage of the fluorogenic substrate acetyl-DEVD-7-amido-4-methyl coumarin in
platelets pretreated with DMSO, sirtinol, EX-527, or ABT-737. F, calpain activity determined from the extent of cleavage of the fluorogenic substrate t-butoxy-
carbonyl-Leu-Met-chloromethylcoumarin in platelets pretreatedwith DMSO, sirtinol, EX-527, or A23187. Data aremean S.D. of five different experiments. *,
p 0.05 compared with DMSO-pretreated resting platelets; ns, not significant.
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tent with a lack of involvement of caspase-3 in changes medi-
ated by Sirt1 inhibition.
Next we looked for calpain activity in platelets undergoing
either sirtinol- or EX-527-induced apoptosis-like changes.
Remarkably, platelets pretreated with sirtinol (50 and 100 M)
were found to possess a significantly higher proteolytic activity
of calpain (by 21.5  5% and 49  5%, respectively) than their
vehicle-treated counterparts (Fig. 4F), therefore implicating
calpain in sirtinol-mediated platelet cell death. Similar results
were observed in EX-527-treated platelets.
Sirtuin Inhibition Leads to a Reduction in the Number of
Reticulated Platelets and Thrombocytopenia—Apoptosis has
now been established as an important regulator of platelet life
span (14, 15, 29, 30) that determines the number of circulating
platelets. Because sirtuin inhibition transforms platelets into
the apoptotic phenotype, we investigated the impact of sirtinol
on platelet count and life span under in vivo condition. Reticu-
lated platelets are an RNA-containing younger cell population,
which were stained with thiazole orange (12). Administration
of either sirtinol (15 mg/kg) or EX-527 (20 mg/kg) into mice
resulted in a decrease in the number of reticulated platelets (by
36.5% and 40.5%, respectively, after 36 h) (Fig. 5A) as well as a
significant reduction in platelet count (by 59.94% in 12 h in
mice administered sirtinol and by 44% in 36 h in mice admin-
istered EX-527) (Fig. 5B). After 36 h of sirtinol or EX-527
administration, the number of reticulated platelets eventually
normalized (Fig. 5A). However, our experiments do not rule out
platelet damage as a cause of sirtinol-induced thrombocytope-
nia in mice. The serum concentration of sirtinol achievable
after the administered dose may not be sufficient or competent
enough to induce strong apoptosis-like events in platelets lead-
ing to platelet clearance compared with the in vitro situation
using human platelets, whereas the same serum concentration
was sufficient to suppress platelet production and cause throm-
bocytopenia. Secondly, the possibility of impaired clearance of
mouse platelets in the presence of sirtinol cannot be ruled out.
A similar result was observed in mice administered AGK-2 (15
mg/kg, data not shown).
Next, we analyzed the platelet life span in mice administered
sirtinol. Mice were injected with intravenous N-hydroxysuc-
cinimidobiotin, allowing biotinylation of circulating platelets.
The decrease in labeled platelets over time in sirtinol-treated
mice was found to be similar to that in vehicle-treated counter-
parts (Fig. 5C). These data indicate that changes in platelet life
span are unlikely to explain sirtinol-induced thrombocytopenia
and is suggestive of decreased production of platelets, as
described in mice treated with HDAC1/2-specific inhibitors
(12).
DISCUSSION
Acetylation of proteins is a posttranslational modification
catalyzed by acetyltransferases and deacetylases. Because of its
reversible character, acetyl transfer regulates several signaling
processes (32). Proteomics studies have identified thousands of
acetylatedmammalian proteins (32). In platelets, aspirin acts as
an acetylating agent that transfers an acetyl group to a serine
residue in the active site of the cyclooxygenase. Recent studies
have revealed widespread abundance of protein lysine-acetyla-
tion as a vital regulation mechanism in different cells (33, 34).
Sirtuin is a NAD-dependent acetyl-lysine deacetylase that
FIGURE 5. Sirt1 inhibition leads to a reduction in reticulated platelets and platelet count. A, relative number of reticulated platelets in a peripheral blood
sampledrawn frommicepretreatedwithDMSO (vehicle), sirtinol (15mg/kg), or EX-527 (20mg/kg) at intervals of 0, 12, 36, 60, and84h.B, relativeplatelet count
in control-, sirtinol-, or EX-527-treatedmice at different time points. C, relative number of biotinylated platelets in a peripheral blood sample drawn frommice
pretreated with DMSO (vehicle) or sirtinol (15 mg/kg) at intervals of 0, 12, 36, 60, and 84 h. Data are mean  S.D. of five different experiments. *, p  0.05
compared with DMSO-pretreated resting platelets.
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belongs to the HDAC III family and is expressed in prokaryotes
as well as eukaryotes. Mammalian sirtuins are linked to healthy
aging, and, therefore, have possible therapeutic implications in
age-related pathologies, metabolic and cardiovascular disor-
ders, and inflammation (4, 35). Platelets are major players in
hemostasis and thrombosis. Although Sirt1, Sirt2, and Sirt3 are
expressed in platelets, the relevance of sirtuin-mediated signal-
ing remains obscure in these cells. Here we report, for the first
time, the regulation of platelet cell death by sirtuins. In addition
to Sirt1, Sirt2 and Sirt3 were also found to be expressed in
enucleate platelets. We demonstrate that sirtinol, AGK2, and
EX-527, pharmacologically distinct inhibitors of Sirt1/Sirt2,
induced apoptosis-like changes in platelets in vitro, which
included a drop in m, enhanced surface exposure of phos-
phatidylserine, and a rise in cytosolic ROS. Calpain, but not
caspase, has been found to be activated in sirtinol or EX-527-
treated platelets, which is consistent with caspase-independent
cell death described in different cells, including platelets (15, 20,
28–30). Because platelet apoptosis is known to be mediated
through proapoptotic members of Bcl-2 (14–15), we evaluated
the effect of sirtuin inhibition on the activation of Bax. Sirtinol-
or EX-527-pretreated platelets were found to express a signifi-
cantly higher level of conformationally active Bax than the con-
trol (untreated) counterparts. Because p53 is a known substrate
of sirtuin and an upstream regulator of Bax (36–37), we asked
next whether Sirt1 inhibition would affect the level of post-
translationally modified p53 in platelets. In line with the above
reasoning, enhanced acetylation of p53 was observed in sirtinol
or EX-527-treated cells. Consistent with apoptosis-like pheno-
types, sirtinol-treated human platelets were found to be phago-
cytosed more efficiently by macrophages, as demonstrated in
vitro by flow cytometry and epifluorescence microscopy.
Administration of mice with either sirtinol or EX-527 led to
thrombocytopenia as well as a decrease in the number of retic-
ulated platelets, although sirtinol had no significant effect on
platelet life span in mice. The drop in number of reticulated
platelets could be attributed to decreased production of plate-
lets, as reported earlier in mice treated with HDAC1/2-specific
inhibitors (12).
Earlier studies, including ours, have attributed delimitation
of platelet life span to activities of pro- and antiapoptotic mem-
bers of the Bcl-2 family (14, 15). Proteasomal peptidase activity
promotes platelet survival through the constitutive elimination
of the conformationally active Bax. Acetyl-p53 is known to play
a determining role in the transcription-independent pathway of
Bax-mediated apoptosis (27). Acetyl-p53 is a substrate of sir-
tuin and an upstream positive regulator of Bax (36–37). On the
basis of the evidence provided in this study, it may be surmised
that sirtuin deacetylase activity regulates platelet life span
through inhibition of p53 acetylation, which, as a consequence,
precludes Bax activation and platelet cell death (Fig. 6). Our
observations support the possibility of enhancement of platelet
life span in the presence of sirtuin activators, whereas platelets
from sirt	/	 mice are anticipated to undergo apoptosis-like
signaling and early clearance. Sirtuin may, therefore, be a
potential therapeutic target to induce apoptosis-like events in
platelets and to reduce the severity of thrombosis or thrombo-
cytosis. It has been reported recently that platelets play a critical
role in cancer cell proliferation, and, therefore, sirtuin inhibi-
tion can indirectly contribute to the anticancer effect by
FIGURE 6. The proposed role of sirtuin in the determination of platelet life span. The sirtuin inhibitor enhances acetylation of p53, which eventually
leads to the activation of proapoptotic Bax and apoptosis-like signaling in platelets. In the absence of acetylation, p53 is ubiquitinated and degraded by
the proteasome, which facilitates cell survival (27). As reported in our earlier studies, proteasomal peptidase activity promotes platelet survival
through constitutive elimination of the conformationally active Bax (15). Therefore, the proteasome and sirtuin both regulate platelet apoptosis and
survival.
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restricting the platelet count (38). Because sirtuin inhibitors are
being actively evaluated for their antitumor activity (7–9), our
observations also call for the careful consideration of their
potentially adverse effect on platelets while exploiting the ben-
efits of sirtuin inhibition in cancer therapeutics.
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